ClinicalTrials.gg
CompletedNCT01709305Updated Aug 21, 2018Results posted

A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

A Phase 4 interventional study of Metformin and Sitagliptin in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-08-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5,570
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing acarbose in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Acarbose · Diabetes Mellitus, Type 2.

Enrollment
2nd of 29
5,570 · median 100
Started
2012
with 4 others
Phase 4
15 of 30
none open now
Registered
15th of 30
by date
Lead sponsor
1 of 30
Merck Sharp & Dohme LLC

Among the 30 studies testing acarbose in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2012, is one of 15 in phase 4, and was the 15th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 30 studies testing acarbose in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About acarbose

Acarbose: first FDA approval 1995 (PRECOSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing acarbose in Diabetes Mellitus, Type 2 as a file.
02

Study summary

To assess the effect of adding acarbose or repaglinide or gliclazide to sitagliptin plus metformin, compared to adding glimepiride, on glycemic improvements in Type 2 Diabetes Mellitus (T2DM) participants who require the addition of a third oral anti-hyperglycemic agent (OAHA) according to China Guideline for Type 2 Diabetes. The three co-primary hypotheses are that after 24 weeks of treatment in phase 2, the mean change from baseline in hemoglobin A1c (A1c) in participants receiving either (1)acarbose or (2)repaglinide or (3)gliclazide added to sitagliptin and metformin combination is non-inferior to that of participants receiving glimepiride added to sitagliptin and metformin combination. The study would be declared successful if at least one of the three primary hypotheses was met.

Read the detailed description

Participants coming on study will be stabilized to a standardized metformin dose: this may take about 10 weeks, and then combination therapy with metformin + sitagliptin will begin during Phase 1 (Week 0 through Week 20). If a participant has already been on a stabilized metformin dose, they will start immediately on combination therapy with metformin + sitagliptin for 20 weeks (Phase 1).

In Phase 2, participants who have failed to achieve adequate glycemic control (A1c ≥ 7% and ≤ 10% at Week 16 and fasting finger stick glucose ≥130 mg/dL and ≤280 mg/dL at Week 20) will be randomized to receive add-on therapy with glimepiride, repaglinide, acarbose, or gliclazide for 24 weeks (Week 20 through Week 44).

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has Type 2 Diabetes Mellitus;
  • Agrees to use an effective method of or must not otherwise be at risk of becoming pregnant (female participants).

Exclusion criteria

Exclusion Criteria:

  • Has a history of type 1 diabetes mellitus or a history of ketoacidosis;
  • Has been treated with insulin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, a Glucagon-like peptide-1 (GLP-1) mimetic or analogue before;
  • Is on a weight loss program (not in maintenance phase), has started a weight loss medication, or has undergone bariatric surgery within 12 months;
  • Has undergone a surgical procedure within 4 weeks;
  • Has had new or worsening signs or symptoms of coronary heart disease or congestive heart failure within past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder;
  • Has a medical history of active liver disease, including chronic active or C, primary biliary cirrhosis, or symptomatic gallbladder disease;
  • Has poorly controlled hypertension;
  • Has severe peripheral vascular disease;
  • Has (HIV);
  • Has had a hematological disorder;
  • Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking;
  • Has a history of intolerance or or any to study medications (including sitagliptin, metformin, glimepiride, repaglinide, acarbose or gliclazide) based upon the Chinese label;
  • Is on or likely to require treatment with ≥2 consecutive weeks or repeated courses of pharmacologic doses of (other than inhaled, nasal, or topical corticosteroids);
  • Is pregnant or breast feeding or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug (female participants).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5,570 participants (actual)

Study arms

  • Active comparator
    Metformin + Sitagliptin + Glimepiride

    During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).

    Drug: Metformin · Drug: Sitagliptin · Drug: Glimepiride

  • Experimental
    Metformin + Sitagliptin + Repaglinide

    During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).

    Drug: Metformin · Drug: Sitagliptin · Drug: Repaglinide

  • Experimental
    Metformin + Sitagliptin + Acarbose

    During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).

    Drug: Metformin · Drug: Sitagliptin · Drug: Acarbose

  • Experimental
    Metformin + Sitagliptin + Gliclazide

    During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).

    Drug: Metformin · Drug: Sitagliptin · Drug: Gliclazide

Interventions

  • Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.

    Also known as: Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®

  • Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food

    Also known as: Januvia®, Tesavel®, Xelevia®, Ristaben®

  • Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.

    Also known as: Precose®, Glucobay™

  • Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.

    Also known as: Prandin®, Fulaidi™

  • Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day

    Also known as: Amaryl®, Glimy

  • Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.

    Also known as: Diamicron MR™

06

What researchers measure

Primary outcomes

  1. Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)

    HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction.

    Time frame: Phase 2 Baseline (Week 20) and Week 44

Secondary outcomes

  1. Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)

    Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used.

    Time frame: Phase 2 Baseline (Week 20), Week 44

  2. Percentage of Participants With Hypoglycemia Events (Phase 2)

    Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported.

    Time frame: From Week 20 through Week 44

  3. Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)

    The percentage of participants with a GI AE of "nausea" was reported.

    Time frame: From Week 20 through Week 44

  4. Percentage of Participants With a GI AE of Vomiting (Phase 2)

    The percentage of participants with a GI AE of "vomiting" was reported.

    Time frame: From Week 20 through Week 44

  5. Percentage of Participants With a GI AE of Diarrhea (Phase 2)

    The percentage of participants with a GI AE of "diarrhea" was reported.

    Time frame: From Week 20 through Week 44

  6. Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)

    The percentage of participants with a GI AE of "abdominal pain" was reported.

    Time frame: From Week 20 through Week 44

07

Results

Posted May 11, 2016

Participant flow

Adult Chinese participants (≥18 and ≤75 years of age) with a diagnosis of Type 2 Diabetes Mellitus (T2DM) and inadequate glycemic control were selected to participate in this study.

Phase 1
Participant flow — Phase 1
MilestonePhase 1: Sitagliptin + MetforminPhase 2: Metformin + Sitagliptin + GlimepiridePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + Gliclazide
Started55700000
Completed49330000
Not completed6370000
Withdrew: Clinical adverse event800000
Withdrew: Death20000
Withdrew: Hyperglycemia (lack of efficacy)130000
Withdrew: Laboratory adverse event160000
Withdrew: Lost to follow-up1470000
Withdrew: Travel, moving, etc.300000
Withdrew: Physician decision130000
Withdrew: Protocol violation1180000
Withdrew: Withdrawal by subject2180000
Phase 2
Participant flow — Phase 2
MilestonePhase 1: Sitagliptin + MetforminPhase 2: Metformin + Sitagliptin + GlimepiridePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + Gliclazide
Started0552550556554
Completed0500505508507
Not completed052454847
Withdrew: Clinical adverse event01010611
Withdrew: Death00100
Withdrew: Hyperglycemia (lack of efficacy)00002
Withdrew: Laboratory adverse event01011
Withdrew: Lost to follow-up010695
Withdrew: Travel, moving, etc.02335
Withdrew: Physician decision02012
Withdrew: Protocol violation01919139
Withdrew: Withdrawal by subject0861512

Outcome measures

PrimaryChange From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)

HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction.

Time frame:
Phase 2 Baseline (Week 20) and Week 44
Reported as:
Least squares mean · Percent
Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)
PercentPhase 2: Metformin + Sitagliptin + GlimepiridePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + Gliclazide
Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)-0.65 ± 0.84-0.62 ± 0.84-0.46 ± 0.83-0.69 ± 0.90
Statistical analysis
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Acarbose · Difference in ls means: 0.19 · 98.34% CI 0.02 to 0.36
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Repaglinide · Difference in ls means: 0.03 · 98.34% CI -0.15 to 0.21
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Gliclazide · Difference in ls means: -0.05 · 98.34% CI -0.23 to 0.14
SecondaryChange From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)

Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used.

Time frame:
Phase 2 Baseline (Week 20), Week 44
Reported as:
Mean · kg
Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)
kgPhase 2: Metformin + Sitagliptin + GlimepiridePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + Gliclazide
Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)0.4 ± 2.60.2 ± 2.5-0.9 ± 2.50.2 ± 2.4
SecondaryPercentage of Participants With Hypoglycemia Events (Phase 2)

Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported.

Time frame:
From Week 20 through Week 44
Reported as:
Number · Percentage of Participants
Percentage of Participants With Hypoglycemia Events (Phase 2)
Percentage of ParticipantsPhase 2: Metformin + Sitagliptin + GlimepiridePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + Gliclazide
Percentage of Participants With Hypoglycemia Events (Phase 2)8.96.10.53.6
Statistical analysis
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Acarbose · Miettinen & Nurminen · p = <0.001 · Estimate: -8.4 · 95% CI -11.1 to -6.1
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Repaglinide · Miettinen & Nurminen · p = 0.072 · Estimate: -2.9 · 95% CI -6.1 to 0.3
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Gliclazide · Miettinen & Nurminen · p = <0.001 · Estimate: -5.3 · 95% CI -8.3 to -2.5
SecondaryPercentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)

The percentage of participants with a GI AE of "nausea" was reported.

Time frame:
From Week 20 through Week 44
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)
Percentage of ParticipantsPhase 2: Metformin + Sitagliptin + GlimepiridePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + Gliclazide
Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)000.40.2
Statistical analysis
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Acarbose · Miettinen & Nurminen · p = 0.158 · Estimate: 0.4 · 95% CI -0.3 to 1.3
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Repaglinide · Miettinen & Nurminen · p = >0.999 · Estimate: 0.0 · 95% CI -0.7 to 0.7
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Gliclazide · Miettinen & Nurminen · p = 0.318 · Estimate: 0.2 · 95% CI -0.5 to 1.0
SecondaryPercentage of Participants With a GI AE of Vomiting (Phase 2)

The percentage of participants with a GI AE of "vomiting" was reported.

Time frame:
From Week 20 through Week 44
Reported as:
Number · Percentage of Participants
Percentage of Participants With a GI AE of Vomiting (Phase 2)
Percentage of ParticipantsPhase 2: Metformin + Sitagliptin + GlimepiridePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + Gliclazide
Percentage of Participants With a GI AE of Vomiting (Phase 2)0.200.20.2
Statistical analysis
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Acarbose · Miettinen & Nurminen · p = 0.998 · Estimate: -0.0 · 95% CI -0.9 to 0.9
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Repaglinide · Miettinen & Nurminen · p = 0.319 · Estimate: -0.2 · 95% CI -1.0 to 0.5
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Gliclazide · Miettinen & Nurminen · p = 0.999 · Estimate: -0.0 · 95% CI -0.9 to 0.9
SecondaryPercentage of Participants With a GI AE of Diarrhea (Phase 2)

The percentage of participants with a GI AE of "diarrhea" was reported.

Time frame:
From Week 20 through Week 44
Reported as:
Number · Percentage of Participants
Percentage of Participants With a GI AE of Diarrhea (Phase 2)
Percentage of ParticipantsPhase 2: Metformin + Sitagliptin + GlimepiridePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + Gliclazide
Percentage of Participants With a GI AE of Diarrhea (Phase 2)0.50.40.40.9
Statistical analysis
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Acarbose · Miettinen & Nurminen · p = 0.651 · Estimate: -0.2 · 95% CI -1.3 to 0.8
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Repaglinide · Miettinen & Nurminen · p = 0.660 · Estimate: -0.2 · 95% CI -1.3 to 0.8
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Gliclazide · Miettinen & Nurminen · p = 0.480 · Estimate: 0.4 · 95% CI -0.8 to 1.6
SecondaryPercentage of Participants With a GI AE of Abdominal Pain (Phase 2)

The percentage of participants with a GI AE of "abdominal pain" was reported.

Time frame:
From Week 20 through Week 44
Reported as:
Number · Percentage of Participants
Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)
Percentage of ParticipantsPhase 2: Metformin + Sitagliptin + GlimepiridePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + Gliclazide
Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)000.40.2
Statistical analysis
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Acarbose · Miettinen & Nurminen · p = 0.158 · Estimate: 0.4 · 95% CI -0.3 to 1.3
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Repaglinide · Miettinen & Nurminen · p = >0.999 · Estimate: 0.0 · 95% CI -0.7 to 0.7
  • Phase 2: Metformin + Sitagliptin + Glimepiride vs Phase 2: Metformin + Sitagliptin + Gliclazide · Miettinen & Nurminen · p = 0.318 · Estimate: 0.2 · 95% CI -0.5 to 1.0

Adverse events

Collected over Up to 46 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Sitagliptin + Metformin—63/5,527 (1.1%)66/5,527 (1.2%)
Phase 2: Metformin + Sitagliptin + Acarbose—11/551 (2%)3/551 (0.5%)
Phase 2: Metformin + Sitagliptin + Repaglinide—9/545 (1.7%)33/545 (6.1%)
Phase 2: Metformin + Sitagliptin + Gliclazide—10/550 (1.8%)20/550 (3.6%)
Phase 2: Metformin + Sitagliptin + Glimepiride—8/549 (1.5%)48/549 (8.7%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventPhase 1: Sitagliptin + MetforminPhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + GliclazidePhase 2: Metformin + Sitagliptin + Glimepiride
Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders2/55270/5513/5451/5501/549
AppendicitisInfections and infestations1/55270/5512/5450/5500/549
Acute Myocardial InfarctionCardiac disorders0/55270/5510/5452/5500/549
Cerebral InfarctionNervous system disorders2/55272/5510/5450/5500/549
Intestinal ObstructionGastrointestinal disorders0/55270/5511/5450/5500/549
Pancreatitis AcuteGastrointestinal disorders0/55270/5511/5450/5500/549
Liver AbscessInfections and infestations0/55270/5511/5450/5500/549
FallInjury, poisoning and procedural complications0/55270/5511/5450/5500/549
Myelodysplastic SyndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/55270/5511/5450/5500/549
Diabetic NeuropathyNervous system disorders0/55270/5511/5450/5501/549
Most frequent other events
Most frequent other events
EventPhase 1: Sitagliptin + MetforminPhase 2: Metformin + Sitagliptin + AcarbosePhase 2: Metformin + Sitagliptin + RepaglinidePhase 2: Metformin + Sitagliptin + GliclazidePhase 2: Metformin + Sitagliptin + Glimepiride
HypoglycemiaMetabolism and nutrition disorders66/55273/55133/54520/55048/549

Baseline characteristics

This population includes all participants who enrolled in Phase 1 and were GCP compliant.

Age, Continuous
Age, Continuous(Years)Overall Study
Mean53.1 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female2240
Male3295
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Xu W, Mu Y, Zhao J, Zhu D, Ji Q, Zhou Z, Yao B, Mao A, Engel SS, Zhao B, Bi Y, Zeng L, Ran X, Lu J, Ji L, Yang W, Jia W, Weng J. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. Sci China Life Sci. 2017 Mar;60(3):225-238. doi: 10.1007/s11427-016-0409-7. Epub 2017 Feb 7. PubMed 28271251 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Apr 2015, 29 months.

Results were first posted in May 2016, 1 year after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 29 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 18, 2012
StartActual
Nov 8, 2012
Primary completionActual
Apr 17, 2015
CompletionActual
Apr 17, 2015
Results first posted
May 11, 2016
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01709305
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Nov 8, 2012
Primary completion
Apr 17, 2015
Completion
Apr 17, 2015
Results posted
May 11, 2016
Last update
Aug 21, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acarbose · Repaglinide · Gliclazide

Start the discussion